Korea Exchange activated a buy-side sidecar on KOSDAQ at 12:55 p.m. Friday as the index rose 5.27% to 800.90, a day after closing down 7.65%. That recovers about 64% of the point loss; the reports do not include turnover data to test the liquidity case.
Reality
- Evidence80
- Adoption
- Not scored
- Hype gap+5
- Incentives
- Not scored
- Confidence80
Seoul's Kospi fell 7.57% to 5,554.22 on Thursday, tripping a sidecar and a 20-minute circuit breaker as Samsung Electronics and SK hynix sank. The reports carry prices and flows but no valuations, and say nothing about whether chip shares were overpriced.
Perspective Coverage
4 publishers
- Builder
- Builder 12%
- Operator
- Operator 21%
- Investor
- Investor 67%
Reality
- Evidence80
- Adoption
- Not scored
- Hype gap+15
- Incentives
- Not scored
- Confidence78
Kospi falls 7.77% in early trading even as domestic buyers absorb most of the foreign selling
Kospi was down 7.77% at 10:30 a.m. Thursday as foreign investors extended net selling to eight sessions, Korea JoongAng Daily reported. Domestic buyers took about 91% of what foreigners sold.
Reality
- Evidence58
- Adoption
- Not scored
- Hype gap+8
- Incentives
- Not scored
- Confidence62
Bankruptcy petitions against KOSDAQ firms end in a bankruptcy ruling about 3% of the time
Korean courts declared bankruptcy in 4 of 131 petitions filed against KOSDAQ companies since January 2016, Korea Exchange data show. Because a filing can halt trading before any judge rules, shareholders outside the creditor dispute bear the cost of weak claims.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+15
- Incentives45
- Confidence55
HLB's fourth rivoceranib filing hinges on two factories' FDA inspection ratings
HLB is preparing a fourth FDA filing for its liver cancer drug rivoceranib after both manufacturing sites tied to it received VAI inspection ratings. Manufacturing problems ran through all three rejections, so those ratings say more about rivoceranib's odds than HLB's first FDA approval does.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+25
- Incentives70
- Confidence50
KOSDAQ's 4.24% October gain leans on chip suppliers up as much as 138% since August
Korea's KOSDAQ rose 4.24% this month through Oct. 11 while the KOSPI fell 3.1%, Korea Exchange figures show. Seoul Economic Daily reported that the buying is concentrated in chip materials and equipment suppliers, so anyone buying the small-cap index is holding a narrow bet on chip spending.
Reality
- Evidence60
- Adoption
- Not scored
- Hype gap+5
- Incentives
- Not scored
- Confidence55
Korea's delisting pause still locks shareholders out of eight stocks
Korea Exchange has deferred further delistings under its tougher market-cap rule, but trading stays suspended in eight companies it had already decided to delist. Their holders cannot sell, and the exchange's plan to challenge the ruling behind the pause leaves no date for trading to resume.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap0
- Incentives
- Not scored
- Confidence60
Back-end chip suppliers lift the KOSDAQ to its first close above 900 since July
South Korea's KOSDAQ closed at 919.92, its first finish above 900 since July, as seven back-end chip suppliers averaged 54.86% gains since Sept. 1. The gains price in more AI spending by the big chipmakers, so the index still depends on Samsung and SK hynix budgets while their shares lag.
Reality
- Evidence62
- Adoption
- Not scored
- Hype gap+15
- Incentives
- Not scored
- Confidence55
Parataxis Ethereum scraps its Parataxis Korea merger over appraisal cash and a delisting fight
Parataxis Ethereum dropped its takeover of Parataxis Korea and a 29.77 million-share issue, citing appraisal claims that could drain its cash. Parataxis Korea's holders keep a stock suspended since Aug. 21 instead of listed shares due in January.
Reality
- Evidence60
- Adoption
- Not scored
- Hype gap0
- Incentives
- Not scored
- Confidence55
Korean ETF buyers put 5.35 trillion won into cash and US index funds that averaged 0.83% in a month
Korea's 10 most-bought ETFs took in 5.35 trillion won over a month and averaged 0.83%, while KOSDAQ supplier funds led the return table at 26% to 32%. Earnings season will test whether 2.17 trillion won parked in two cash funds follows them.
Reality
- Evidence60
- Adoption
- Not scored
- Hype gap+25
- Incentives
- Not scored
- Confidence55
Seoul court voids the Korea Exchange rule that delisted firms for falling below a market-cap floor
Seoul's Southern District Court voided the Korea Exchange's market-cap delisting rule, freezing two removals as about 30 KOSDAQ firms face the same test. Until the exchange adds a right of objection, any removal on market value alone is likely to end up before a judge.
Reality
- Evidence58
- Adoption
- Not scored
- Hype gap+20
- Incentives45
- Confidence60
Korea's $60.3 billion chip-export month carried the KOSPI to within 29 points of 7,000
KOSPI rose 1.95% to 6,971.35 on October 1 as Korea's September chip exports hit a record $60.3 billion, reversing a yield-driven early dip. The session shows chip news can beat US rate pressure for a day. How long it can keep doing so depends on how long the memory shortage lasts.
Reality
- Evidence62
- Adoption
- Not scored
- Hype gap+15
- Incentives
- Not scored
- Confidence60
Korea's second National Growth Fund widens the loss buffer under retail savers to as much as 23.3%
Samsung, Mirae Asset and KB are selling a 600 billion won National Growth Fund II with a loss buffer of 18.8% to 23.3%, up from 17.5% to 20.8%. State money and manager capital sit beneath savers, who also collect tax breaks for locking money up for five years.
Reality
- Evidence58
- Adoption
- Not scored
- Hype gap+12
- Incentives65
- Confidence60
Two Korean biotech IPOs raised 24.5 billion won less than the top of their ranges
Skylabs and Ingenia Therapeutics priced at or below the floor of their indicative ranges after institutions pledged 0.17% and 2.23% of bids to lockups. Both stocks have since traded above the top of those ranges.
Reality
- Evidence58
- Adoption46
- Hype gap+22
- Incentives52
- Confidence62
One KOSDAQ IPO has raised more than a trillion won since the board opened in 1996
Celltrion Healthcare's 1.0088 trillion won in 2017 still stands alone, and Yanolja, Viva Republica and Galaxy Corporation are all pursuing US listings while KOSDAQ turnover runs at less than half January's.
Reality
- Evidence34
- Adoption
- Not scored
- Hype gap+28
- Incentives62
- Confidence38
DS Asset Management opens its AI chip ETF with 30% in Samsung and SK hynix
The Korean manager's second ETF lists next month with SK hynix and Samsung Electronics at 15% apiece, half the 60% it must keep in domestic stocks. The discretion it is selling sits in the eight suppliers around them.
Reality
- Evidence40
- Adoption18
- Hype gap+15
- Incentives65
- Confidence42
Korea Exchange eases cash deposit rule for all flagged stocks as retail investors keep buying some anyway
Of 1,548 caution and risk designations since 2022, prices were lower 20 trading days later in 1,050 cases and down more than 30% in 398, while individuals were net buyers of 13 of the 41 stocks flagged in August.
Reality
- Evidence60
- Adoption55
- Hype gap+12
- Incentives62
- Confidence55
Two stocks, PonyLink and Valofe, swung more than 32% in the four hours KRX added to the trading day
KRX scrapped 10-minute single-price matching for continuous trading between 4 p.m. and 8 p.m., and on the first day the biggest movers round-tripped, with Hanwha Galleria finishing about 0.9% below its regular-session close.
Reality
- Evidence52
- Adoption48
- Hype gap+12
- Incentives58
- Confidence50
SK hynix sheds 95,000 won at the open as hike odds jump to 86% from 69%
Core CPI at 0.3% for August pushed futures to 86% from 69% on a September Fed hike, and Seoul's open took SK hynix down 5.24% to 1.717 million won. Philadelphia's semiconductor index had closed 1.81% higher on the 11th.
Reality
- Evidence58
- Adoption
- Not scored
- Hype gap+14
- Incentives32
- Confidence60
Korea Exchange replaces twelve evening auctions with four hours of continuous matching
From September 14 KRX will match orders continuously between 4 and 8 p.m., taking limit orders only, capping moves at 30% and leaving ETFs and ETNs out, with 38 brokerages covering 95.2% of volume signed up.
Reality
- Evidence42
- Adoption30
- Hype gap+20
- Incentives55
- Confidence45